Alternative splicing factor ASF/SF2 is down regulated in inflamed muscle

Journal of Clinical Pathology

Volumn 59, Issue 8, 2006, Pages 855-861

  Xiong, Z ^a,b   Shaibani, A ^b,c   Li, Y P ^b   Yan, Y ^b   Zhang, S ^a,b   Yang, Y ^b   Yang, F ^a,b   Wang, H ^a,b   Yang, X F ^a,b  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c ST LUKE S EPISCOPAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; NUCLEAR PROTEIN; PROTEIN ALTERNATIVE SPLICING FACTOR 2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ALTERNATIVE RNA SPLICING; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MALE; MOUSE; MUSCLE BIOPSY; MYOSITIS; MYOTUBE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SPLICEOSOME; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; ALTERNATIVE SPLICING; ANIMALS; AUTOIMMUNE DISEASES; BIOPSY; CELLS, CULTURED; DOWN-REGULATION; FEMALE; HUMANS; MALE; MICE; MIDDLE AGED; MUSCLE FIBERS; MUSCLE, SKELETAL; MYOSITIS; NUCLEAR PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33747032570     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2005.032961     Document Type: Article

References (50)

1. Von Muhlen CA, Tan EM. Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum 1995;24:323-58.
2. Schellekens GA, Visser H, de Jong BA, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43:155-03.
3. Brouwer R, Pruijn GJ, van Venrooij WJ. The human exosome: an autoantigenic complex of exoribonucleases in myositis and scleroderma. Arthritis Res 2001;3:102-6.
4. Mahler M, Bluthner M, Pollard KM. Advances in B-cell epitope analysis of autoantigens in connective tissue diseases. Clin Immunol 2003;107:65-79.
5. Mitchell P, Tollervey D. Musing on the structural organization of the exosome complex. Not Struct Biol 2000;7:843-6.
6. Hilleren P, McCarthy T, Rosbash M, et al. Quality control of mRNA 3′-end processing is linked to the nuclear exosome. Nature 2001;413:538-42.
7. Mukherjee D, Gao M, O'Connor JP, et al. The mammalian exosome mediates the efficient degradation of mRNAs that contain AU-rich elements. EMBO J 2002;21:165-74.
8. Vasudevan S, Peltz SW. Nuclear mRNA surveillance. Curr Opin Cell Biol 2003;15:332-7.
9. Black DL. Mechanisms of alternative pre-messenger RNA splicing. Annu Rev Biochem 2003;14:273-82.
10. Ng B, Yang F, Huston DP, et al. Increased noncanonical splicing of autoantigen transcripts provides the structural basis for expression of untolerized epitopes. J Allergy Clin Immunol 2004;114:1463-70.
11. Raijmakers R, Renz M, Wiemann C, et al. PM-Scl-75 is the main autoantigen in patients with the polymyositis/scleroderma overlap syndrome. Arthritis Rheum 2004;50:565-9.
12. Raijmakers R, Egberts WV, van Venrooij WJ, et al. The association of the human PM/Scl-75 autoantigen with the exosome is dependent on a newly identified N terminus. J Biol Chem 2003;278:30698-704.
13. Alderuccio F, Chan EK, Tan EM. Molecular characterization of an autoantigen of PM-Scl in the polymyositis/scleroderma overlap syndrome: a unique and complete human cDNA encoding an apparent 75-kD acidic protein of the nucleolar complex. J Exp Med 1991;173:941-52.
14. Fu XD. The superfamily of arginine/serine-rich splicing factors. RNA 1995;1:663-80.
15. Caceres JF, Misteli T, Screaton GR, et al. Role of the modular domains of SR proteins in subnuclear localization and alternative splicing specificity. J Cell Biol 1997;138:225-38.
16. Caceres JF, Kornblihtt AR. Alternative splicing: multiple control mechanisms and involvement in human disease. Trends Genet 2002;18:186-93.
17. Mayeda A, Krainer AR. Regulation of alternative pre-mRNA splicing by hnRNP A1 and splicing factor SF2. Cell 1992;68:365-75.
18. Caceres JF, Stamm S, Helfman DM, et al. Regulation of alternative splicing in vivo by overexpression of antagonistic splicing factors. Science 1994;265:1706-9.
19. Yang X, Bani MR, Lu SJ, et al. The A1 and A1B proteins of heterogeneous nuclear ribonucleoparticles modulate 5′ splice site selection in vivo. Proc Natl Acad Sci USA 1994;91:6924-8.
20. Denegri M, Chiodi I, Corioni M, et al. Stress-induced nuclear bodies are sites of accumulation of pre-mRNA processing factors. Mol Biol Cell 2001;12:3502-14.
21. Weighardt F, Cobianchi F, Cartegni L, et al. A novel hnRNP protein (HAP/SAF-B) enters a subset of hnRNP complexes and relocates in nuclear granules in response to heat shock. J Cell Sci 1999;112(Pt 10):1465-76.
22. Paul WE, Seder RA. Lymphocyte responses and cytokines. Cell 1994;76:241-51.
23. Lundberg IE. The role of cytokines, chemokines, and adhesion molecules in the pathogenesis of idiopathic inflammatory myopathies. Curr Rheumatol Rep 2000;2:216-24.
24. Engel AG, Armstrong CF. The muscle biopsy. In: Engel AG, Armstrong CF, eds. Myology. 3rd edn. New York: McGraw-Hill, 2004:681-90.
25. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003;362:971-82.
26. Li YP, Reid MB. NF-kappaB mediates the protein loss induced by TNF-alpha in differentiated skeletal muscle myotubes. Am J Physiol Regul Integr Comp Physiol 2000;279:R1165-70.
27. Li YP, Chen Y, John J, et al. TNF-alpha acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. FASEB J 2005;19:362-70.
28. Yang XF, Wu CJ, McLaughlin S, et al. CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia. Proc Natl Acad Sci USA 2001;98:7492-7.
29. Engel AG, Armstrong CF. Myology. 3rd edn. New York: McGraw-Hill, Medical Publishing Division, 2004.
30. Brouwer R, Hengstman GJ, Vree Egberts W, et al. Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 2001;60:116-23.
31. Nagaraju K, Raben N, Loeffler L, et al. Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. Proc Natl Acad Sci USA 2000;97:9209-14.
32. Langen RC, Schols AM, Kelders MC, et al. Inflammatory cytokines inhibit myogenic differentiation through activation of nuclear factor-kappaB. FASEB J 2001;15:1169-80.
33. Casciola-Rosen L, Andrade F, Ulanet D, et al. Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity. J Exp Med 1999;190:815-26.
34. Utz PJ, Gensler TJ, Anderson P. Death, autoantigen modifications, and tolerance. Arthritis Res 2000;2:101-14.
35. Plotz PH. The autoantibody repertoire: searching for order. Nat Rev Immunol 2003;3:73-8.
36. Moudgil K, Sercarz EE. Antigenic determinants involved in induction and propagation of autoimmunity. In: Rose N, Mackay IR, eds. The autoimmune diseases. 3rd edn. San Diego: Academic Press, 1998:45-58.
37. Stamm S. Signals and their transduction pathways regulating alternative splicing: a new dimension of the human genome. Hum Mol Genet 2002;11:2409-16.
38. Modrek B, Lee C. A genomic view of alternative splicing. Nat Genet 2002;30:13-9.
39. Scofield RH, Farris AD, Horsfall AC, et al. Fine specificity of the autoimmune response to the Ro/SSA and La/SSB ribonucleoproteins. Arthritis Rheum 1999;42:199-209.
40. Zinkernagel RM, Hengartner H. Regulation of the immune response by antigen. Science 2001;293:251-3.
41. Ladd AN, Cooper TA. Finding signals that regulate alternative splicing in the post-genomic era. Genome Biol 2002;3:reviews0008.
42. Ng B, Fan Yang, Huston DP, et al. Increased non-canonical splicing of autoantigen transcripts provides the structural basis for expression of untolerized epitopes. J Allergy Clin Immunol 2004;11:1463-70.
43. Yan Y, Phan L, Yang F, et al. A novel mechanism of alternative promoter and splicing regulates the epitope generation of tumor antigen CML66-L J Immunol 2004;172:651-60.
44. Klein L, Klugmann M, Nave KA, et al. Shaping of the autoreactive T-cell repertoire by a splice variant of self protein expressed in thymic epithelial cells. Nat Med 2000;6:56-61.
45. Cui L, Yu WP, DeAizpurua HJ, et al. Cloning and characterization of islet cell antigen-related protein-tyrosine phosphatase (PTP), a novel receptor-like PTP and autoantigen in insulin-dependent diabetes. J Biol Chem 1996;271:24817-23.
46. Kanopka A, Muhlemann O, Akusjarvi G. Inhibition by SR proteins of splicing of a regulated adenovirus pre-mRNA. Nature 1996;381:535-8.
47. Shin C, Manley JL. Cell signalling and the control of pre-mRNA splicing. Nat Rev Mol Cell Biol 2004;5:727-38.
48. Robinson WH, DiGennaro C, Hueber W, et al. Autoantigen microarrays for multiplex characterization of autoantibody responses. Nat Med 2002;8:295-301.
49. Robinson WH, Steinman L, Utz PJ. Proteomics technologies for the study of autoimmune disease. Arthritis Rheum 2002;46:885-93.
50. Vacek M, Sazani P, Kole R. Antisense-mediated redirection of mRNA splicing. Cell Mol Life Sci 2003;60:825-33.